Spyre Therapeutics, Inc. - Common Stock (SYRE)
27.27  -0.38 (-1.37%)

Spyre Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies that target specific diseases with an emphasis on precision medicine. The company is dedicated to advancing treatments through cutting-edge research and development, harnessing the potential of novel drug candidates to address unmet medical needs. By leveraging advanced technology and a deep understanding of disease mechanisms, Spyre Therapeutics aims to improve patient outcomes and quality of life across various therapeutic areas. The company's commitment to scientific excellence and collaboration drives its mission to bring transformative solutions to healthcare.

SummaryNewsPress ReleasesChartHistorical
Previous Close27.65
Open27.70
Bid25.97
Ask28.68
Day's Range26.93 - 29.06
52 Week Range14.22 - 47.97
Volume554,699
Market Cap-
PE Ratio (TTM)-
EPS (TTM)-
Dividend & YieldN/A (N/A)
1 Month Average Volume729,611

News & Press Releases

SPYRE ALERT: Bragar Eagel & Squire, P.C. is Investigating Spyre Therapeutics, Inc. on Behalf of Spyre Stockholders and Encourages Investors to Contact the Firm
NEW YORK, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (NASDAQ:SYRE) on behalf of Spyre stockholders. Our investigation concerns whether Spyre has violated the federal securities laws and/or engaged in other unlawful business practices.
By Bragar Eagel & Squire · Via GlobeNewswire · December 3, 2024
SYRE Stock Earnings: Spyre Therapeutics Beats EPS for Q2 2024investorplace.com
SYRE stock results show that Spyre Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.
Via InvestorPlace · August 7, 2024
NewAmsterdam Pharma Announces Appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors
NAARDEN, The Netherlands and MIAMI, July 18, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced the appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors. Mr. McKenna and Mr. Joustra have joined as temporary non-executive directors to fulfill vacant positions within the Board of Directors until their proposed appointment by the general meeting of shareholders at the next annual general meeting. Additionally, NewAmsterdam announced the departure of Sander Slootweg from its Board of Directors, effective July 16, 2024.
By NewAmsterdam Pharma N.V. · Via GlobeNewswire · July 18, 2024
SYRE Stock Earnings: Spyre Therapeutics Misses EPS for Q1 2024investorplace.com
SYRE stock results show that Spyre Therapeutics missed analyst estimates for earnings per share the first quarter of 2024.
Via InvestorPlace · May 9, 2024
NIO Reports Upbeat Earnings, Joins Dave, V2X, Riskified And Other Big Stocks Moving Higher On Tuesdaybenzinga.com
U.S. stocks were lower, with the Dow Jones index falling more than 200 points on Tuesday.
Via Benzinga · March 5, 2024